Herpes simplex virus encephalitis after allogeneic transplantation: an instructive case

Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.
Bone marrow transplantation (Impact Factor: 3.47). 09/2009; 45(4):776-8. DOI: 10.1038/bmt.2009.208
Source: PubMed
Download full-text


Available from: Rizwan Romee, Apr 15, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Therapeutic advances in transplantation medicine have resulted in ever expanding patient populations that receive organ or stem cell transplantation. Modern potent immunomodulatory therapies have resulted in improvements in allograft and patient survival, but, consequently, as a result of the immunosuppressive state, transplant recipients are highly vulnerable to infection, including those that affect the central nervous system (CNS). CNS infections present a diagnostic and therapeutic challenge for clinicians involved in the care of the transplant patient, with a propensity to result in profound morbidity and often high mortality in this patient population. Here, we review major opportunistic pathogens of the CNS seen in transplant patients, highlighting distinguishing epidemiologic and clinical features.
    Current Neurology and Neuroscience Reports 09/2013; 13(9):376. DOI:10.1007/s11910-013-0376-x · 3.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Limited data are available on characteristics of viral encephalitis in patients after allogeneic stem cell transplantation. We analyzed 2,628 patients after allogeneic stem cell transplantation to identify risk factors and characteristics of viral encephalitis. Viral encephalitis occurred in 32 patients (1.2%, 95% confidence interval 0.8%-1.6%) and was associated with the use of OKT-3 or alemtuzumab for T-cell depletion (P < 0.001) and an increased mortality (P = 0.011) in comparison to patients without viral encephalitis. Detected viruses included human herpesvirus-6 (28%), Epstein-Barr virus (19%), herpes simplex virus (13%), JC virus (9%), varicella zoster virus (6%), cytomegalovirus (6%) and adenovirus (3%). More than one virus was identified in 16% of the patients. The median onset time was 106 days after allogeneic stem cell transplantation for the total group of 32 patients, but onset times were shortest in those with human herpesvirus-6 encephalitis and longest in those with JC virus-associated progressive multifocal leukoencephalopathy. The probability of a sustained response to treatment was 63% (95% confidence interval 44%-82%) with a median survival of 94 (95% confidence interval 36-152) days after onset, but significant variation was found when considering different causative viruses. Patients with herpes simplex virus encephalitis had the most favorable outcome with no encephalitis-related deaths. The use of OKT-3 or alemtuzumab for in vivo T-cell depletion is associated with an increased risk of viral encephalitis after allogeneic stem cell transplantation. Different viruses are frequently associated with distinct characteristics such as onset time, response to treatment and outcome.
    Haematologica 01/2011; 96(1):142-9. DOI:10.3324/haematol.2010.029876 · 5.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Herpes simplex encephalitis (HSE) is a rare complication of neurosurgical procedures but must be considered in early deterioration of the postoperative patient. This is the first report of HSE following spinal cord tumor resection. A 65-year-old woman had C2-C5 laminectomy for subtotal resection of intramedullary ependymoma. Six days postoperatively she developed fever, vomiting and rapid decline in mental status. Brain MRI revealed enhancement of left insular cortex. Polymerase chain reaction on cerebrospinal fluid (CSF) identified herpes simplex virus type 1 (HSV-1) as the causal agent. Twenty-one days of acyclovir led to improvement. Three subsequent admissions to neurological intensive care unit were required for deterioration in mental status, including pneumonia, hydrocephalus and deep vein thromboses. Ventriculoperitoneal shunt (VPS), tracheotomy, percutaneous intravenous central catheter (PICC) line and percutaneous endoscopic gastrostomy (PEG) were placed. She was discharged to skilled nursing home care. Acyclovir is effective therapy against HSV, though outcomes may be poor even in optimally treated cases. Empiric treatment must be started even in the absence of serologic evidence of HSV infection if suspicion for HSE is high.
    Journal of Neuro-Oncology 10/2010; 103(3):771-6. DOI:10.1007/s11060-010-0438-8 · 2.79 Impact Factor